ClinicalTrials.gg
Not yet recruitingNCT07326124STEP-ASSISTUpdated Oct 8, 2026

Stratification and Treatment in Early Psychosis Study -ASSIST

A Phase 3 interventional study of CBD 100 mg/mL Oral Solution and Placeb in Treatment Resistant Psychosis and Psychosis, sponsored by University of Oxford. Not yet recruiting at 15 sites in 8 countries. Open to participants aged 16 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by University of Oxford · Phase 3, Interventional, and Treatment

How we know

Updated Oct 8, 2026Start date movedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
16 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing cannabidiol in Psychotic Disorders — 4 open to participants now, 5 under way, 4 of them phase 3. Cannabidiol · Psychotic Disorders.

Planned enrollment
2nd of 11
250 · median 64
Started
2027
the only one that year
Phase 3
4 of 11
4 open now
Registered
10th of 11
by date
Lead sponsor
3 of 11
University of Oxford

Among the 11 studies testing cannabidiol in Psychotic Disorders, this one is the 2nd largest by planned enrollment, is the only one that started in 2027, is one of 4 in phase 3, and was the 10th registered.

Psychotic Disorders

1,593 studies on the registry are indexed under Psychotic Disorders; 283 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

4 of the 11 studies testing cannabidiol in Psychotic Disorders are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 16 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing cannabidiol in Psychotic Disorders, or all of them as a file.
02

Study summary

The purpose of this trial is:

  • To investigate whether the response to clozapine treatment can be enhanced by adding cannabidiol (CBD), compared to placebo, in treatment resistant psychosis patients.
  • To confirm the safety of CBD in people with psychosis.

The trial is a randomised, double-blind, placebo-controlled, multi-centre, international, clinical trial. Individuals with a diagnosis of treatment resistant psychosis in their illness who have had a suboptimal or no response to clozapine treatment will be recruited. These patients are randomised to treatment with oral CBD 500mg twice daily, or a matching placebo for 12 weeks, in addition to clozapine, which is standard care treatment for this population. By using a battery of clinical outcome assessments, the trial will assess several optional biomarkers to predict clinical outcomes and response to treatment with CBD. Biomarkers are being assessed as an exploratory outcome measure. Participants will be invited to provide additional blood samples, stool samples, and complete neuroimaging assessments.

03

Conditions studied

  • Treatment Resistant Psychosis
  • Psychosis

Browse trials for

04

Who can participate

Ages eligible
16 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Participation in the trial requires meeting all of the following inclusion criteria:

  1. 16 to 50 years of age (inclusive) who are willing and able to provide written /assent (country specific requirements apply).
  2. The patient has been treated with clozapine for at least 8 weeks with a clozapine plasma concentration of at least 0.35 mg/L at screening. If a patient has a lower plasma concentration at screening, the patient can enter the trial at a later date once their plasma concentration is above the threshold*.
  3. Within 10 years of first antipsychotic treatment prescribed for psychosis.
  4. The patient meets criteria for schizophrenia, schizoaffective disorder or schizophreniform disorder, as confirmed through the SCID-5-RV. The patient does not meet modified Andreasen et al (2005) criteria for symptomatic remission cross-sectionally (time requirement does not apply), i.e., a severity rating score of no more than mild (score of \</=3) on 8 specified Positive and Negative Syndrome Scale (PANSS) positive and negative symptom items: P1 - Delusions, P2 - Conceptual Disorganization, P3 - Hallucinatory Behaviour, N1 - Blunted Affect, N4 - Passive/Apathetic Social Withdrawal, N6 - Lack of Spontaneity and Flow of Conversation, G5 - Mannerisms and Posturing, G9 - Unusual Thought Content.
  5. Patients of ** must be willing to ensure that they use highly effective during the trial and as per the requirements in the protocol***.
  6. In the Investigator's opinion, is able and willing to comply with all trial requirements.
  7. Willing to allow their General Practitioner and/or consultant, if required by local guidelines/regulations, to be notified of participation in the trial.
  8. For patients who take part in the optional MRI scans: they must be eligible for MRI scanning as per local requirements, for example concerning e.g. implants, braces etc.

There is inadequate information on the effects of cannabidiol on the foetus in humans. Participants of child-bearing potential** should use a highly effective method of contraception3 for the duration of the trial and for 3 months after the last time the trial intervention was used. There is no special requirement for male participants to use highly effective contraception as there are no known safety concerns in males, such as sperm toxicity, as per the Investigator's Brochure. This trial will also not be collecting pregnancy data from partners of male participants.

*Clozapine levels can be up to 4 weeks old if the clozapine dose remained within 25 mg of the dose used at the time of blood draw.

**A person is considered of child-bearing potential, i.e. fertile, following menarche and until becoming (no menses for 12 months without an alternative medical cause) unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.

***Methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include: 1) combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral; intravaginal; transdermal); 2) progestogen-only hormonal contraception associated with inhibition of ovulation (oral; injectable; implantable); 3) intrauterine device (IUD); 4) intrauterine hormone-releasing system (IUS); 5) bilateral tubal occlusion; 6) vasectomised partner; 7) sexual abstinence (abstinence should only be used as a contraceptive method if it is in line with the subjects' usual and preferred lifestyle).

Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. The participant agrees to use an acceptable method of contraception** for the duration of the trial and for 3 months after any trial intervention administration, unless surgically sterile or postmenopausal.

The age range for eligibility has been applied as this corresponds to the usual age range for treatment resistant psychosis; individual cases outside of this age range may have a different aetiology and/or prognosis which could impact on the trial outcomes.

Exclusion Criteria: Individuals are excluded from participation in the trial if they meet one or more of the following exclusion criteria. Rescreening is permitted where the relevant circumstances may have changed.

  1. Current treatment with sodium valproate, valproate semisodium, or clobazam. In cases of current use of these medicines, participation is only permitted if they can and will be discontinued or switched to a suitable alternative medication prior to randomisation.
  2. to the active substance, sesame oil, sesame seed or any of the of the trial intervention.
  3. Known hepatic insufficiency and/or transaminase elevations levels exceeding the 2 times or more and greater than 1.5 times the upper limit of normal.
  4. Previous neurosurgery or neurological disorder, including epilepsy, which may affect the trial procedures*.
  5. IQ \<70 as measured by a validated IQ test e.g. Wechsler Abbreviated Scale of Intelligence (WASI), Wechsler Adult Intelligence Scale (WAIS), and Wechsler Intelligence Scale for Children (WISC), as approved for local languages and appropriate for the participant's age.
  6. Pregnancy or breastfeeding.
  7. The patient has a current diagnosis of 'Substance or medication induced psychotic disorder' or 'Psychotic disorder due to another medical condition' as determined through the SCID-5-RV.
  8. Current active suicidal ideation within the last 2 weeks, defined as a score of 1 or higher on CDSS question 8, followed by an assessment by the treating clinician who determines it is not safe for the patient to participate in the trial**
  9. The participant meeting DSM-5 criteria for substance use disorder, with the exception of nicotine use disorder (mild, moderate, and severe allowed). Mild cannabis use disorder is allowed (i.e. can meet up to but no more than 3 criteria on the SCID) as long as the subject has not consumed cannabis on average more than three times a week in the past 30 days. Mild alcohol use disorder is also allowed.
  10. Patient has participated in another clinical trial in which the participant received an experimental or drug or agent \<3 months before Visit 0. Participants who have participated in Type A studies (e.g. trials of standard and within-label treatments including antipsychotic medication) or non CTIMPs (e.g. studies of exercise therapy) must have completed the intervention.
  11. The participant refuses any mandatory safety checks during the trial, specifically, refusal of: urine pregnancy test (those of child-bearing potential only); safety blood test; reporting of adverse events; and assessment of suicidality.
  12. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.

    • Minor neurological disorders such as migraine, other minor headache disorders, sleep disorders or nerve palsies which are unlikely to affect trial outcomes including neuroimaging measures can be permitted.

      • The decision to include the patient is at clinician's discretion. The clinician can conclude that it is safe for the patient to participate after the patient is evaluated, in which case this exclusion criterion does not apply and the patient can participate. Either way, the treating clinician needs to record his/her evaluation of suicidal risk in the source documentation or medical file, including his/her considerations, and notify the site PI of the decision.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    Experimental: Cannobidiol

    Participants in this arm will receive Cannabidiol (CBD) for 12 weeks.

    Drug: CBD 100 mg/mL Oral Solution

  • Placebo comparator
    Placebo

    Participants in this arm will receive placebo for 12weeks.

    Drug: Placeb

Interventions

  • DrugCBD 100 mg/mL Oral Solution

    Drug page: CannabidiolStudies of CannabidiolCannabidiol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Daily dose 1000mg, taken as 500mg (5ml) b.i.d for 6 weeks. For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 12 weeks

  • DrugPlaceb

    5ml b.i.d for 6 weeks; For participants with a weight lower than 50 kg, the dose is to be adjusted to 20 mg/kg/day divided over 2 intakes of 10 mg/kg/day, for a period of 12 weeks

06

What researchers measure

Primary outcomes

  1. Change in Positive and Negative Syndrome Scale (PANSS) total score

    Change in Positive and Negative Syndrome Scale (PANSS) total score from baseline to 12 weeks. The minimum value is 1 and the maximum value is 7 for each item of the scale. 1. A patient meets remission criteria if none of the following items score a 4 or higher: P1, P2, P3, N1, N4, N6, G5 and G9. 2. A patient does not meet remission criteria if one or more of these items score a 4 or higher.

    Time frame: 12 weeks

Secondary outcomes

  1. Change in symptoms (sub-scale scores)

    Change in scores on the Positive and Negative Syndrome Scale (PANSS) positive, negative and general symptom subscales from baseline to 12 weeks. Total PANSS score: Minimum: 30 (all items scored 1); Maximum: 210 (all items scored 7). Subscale ranges: Positive Scale: 7-49; Negative Scale: 7-49; General Psychopathology Scale: 16-112. Higher PANSS scores = worse outcome; Indicate greater symptom severity. Lower PANSS scores = better outcome; Indicate fewer or less severe symptoms.

    Time frame: From baseline to 12 weeks

  2. Symptomatic remission

    Symptomatic remission after 12 weeks as measured using the Positive and Negative Syndrome Scale (PANSS), defined using Andreasen (2005) remission criteria. Remission is based on the following PANSS: Positive symptoms: P1, P2, P3. Negative symptoms: N1, N4, N6. General psychopathology: G5, G9.Minimum score: 1 (absent); Maximum score: 7 (extreme). Lower scores are better outcome; Higher scores are worse outcome. Andreasen, N. C., Carpenter, W. T., Jr, Kane, J. M., Lasser, R. A., Marder, S. R., \& Weinberger, D. R. (2005). Remission in schizophrenia: proposed criteria and rationale for consensus. The American journal of psychiatry, 162(3), 441-449. https://doi.org/10.1176/appi.ajp.162.3.441

    Time frame: 12 weeks

  3. Change in overall clinical impression

    Change in overall clinical impression, assessed through Clinical Global Impression of Improvement and Severity (CGI-I/S) scales from baseline to 12 weeks. Clinical Global Impression of Severity (CGI-S) is rated from 1 (normal, not at all ill) to 7 (among the most extremely ill), with lower scores indicating lower illness severity. Clinical Global Impression of Improvement (CGI-I) is rated from 1 (very much improved) to 7 (very much worse), with lower scores indicating greater clinical improvement.

    Time frame: From baseline to 12 weeks

  4. Change in functioning

    Change in functioning, assessed through Social and Occupational Function Scale (SOFAS) from baseline to 12 weeks. Score range 1-100, the higher score means the better function

    Time frame: from baseline to 12 weeks

  5. Change in cognitive functioning

    Change in cognitive functioning as assessed through the PsyCog battery from baseline to 12 weeks. PsyCog comprises the tests that were chosen from the larger CANTAB battery to assess the key cognitive deficits associated with psychosis, including: o Paired Associates Learning (PAL): key measures including PAL total errors adjusted (score range 0-70; lower is better) and PAL first attempt memory score (score range 0-20; higher is better).

    Time frame: from baseline to 12 weeks

  6. Change in cognitive functioning

    Change in cognitive functioning as assessed through the PsyCog battery from baseline to 12 weeks. PsyCog comprises the tests that were chosen from the larger CANTAB battery to assess the key cognitive deficits associated with psychosis, including: o Rapid Visual Information Processing (RVP): key measures including RVP A' (score range 0-1; higher is better) and RVP median response latency(ms) (score range 100-1900; lower is better).

    Time frame: from baseline to 12 weeks

  7. Change in cognitive functioning

    Change in cognitive functioning as assessed through the PsyCog battery from baseline to 12 weeks. PsyCog comprises the tests that were chosen from the larger CANTAB battery to assess the key cognitive deficits associated with psychosis, including: Emotion Recognition Task (ERT): key measures including ERT overall median reaction time (ms) (score range 100-00; lower is better) and ERT total hits (score range 0-48; higher is better).

    Time frame: from baseline to 12 weeks

  8. Change in quality of life

    Change in quality of life, assessed using the EuroQol 5-Dimension, 3-Level Questionnaire (EQ-5D-3L) from baseline to 12 weeks. It includes five dimensions-MOBILITY, SELF-CARE, USUAL ACTIVITIES, PAIN /DISCOMFORT and ANXIETY / DEPRESSION. Each dimension has three levels: no problems, some problems, extreme problems (labelled1-3). The respondent is asked to indicate his / her health state by checking the box against the most appropriate statement in each of the five dimensions. The EQ VAS records the respondent's self-rated health on a vertical VAS where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. This information can be used as a quantitative measure of health outcome as judged by the individual respondents. Score range: Minimum: 0 (worst imaginable health); Maximum: 100 (best imaginable health). Higher scores indicate better health; Lower scores indicate worse health.

    Time frame: from baseline to 12 weeks

  9. Change in quality of life

    Change in quality of life, assessed using the World Health Organization Quality-of-Life Scale (WHOQOL-BREF) from baseline to 12 weeks. The WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health (7 items), psychological health (6 items), social relationships (3 items), and environmental health (8 items); it also contains QOL and general health items. Each individual item of the WHOQOL-BREF is scored from 1 to 5 on a response scale, which is stipulated as a five-point ordinal scale.

    Time frame: from baseline to 12 weeks

  10. Acceptability of CBD treatment

    Acceptability of CBD treatment, measured through Clinician rating scale (CRS) to assess adherence to trial medication (Kemp et al., 1998) and all-cause discontinuation over 12 weeks. Clinical rating scale score range: Minimum: 1; Maximum: 7. Higher scores are better outcome; Indicate greater adherence to trial medication. Lower scores are worse outcome; Indicate poor or absent adherence.

    Time frame: 12 weeks

  11. Incidence of adverse events

    Incidence of adverse events, measured through Glasgow Antipsychotic Side-effect Scale (GASS) over 12 weeks. Spontaneous adverse event reporting is until 30 days after the study intervention has been discontinued.

    Time frame: 12 weeks and 30 days post treatment

  12. Changes in measuring the severity of anxiety and depression symptoms

    Measure the severity of anxiety symptoms via Hamilton Anxiety Scale (HAM-A) from baseline to 12 weeks. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe.

    Time frame: from baseline to 12 weeks

  13. Changes in measuring the severity of anxiety and depression symptoms

    Measure the severity of anxiety symptoms via the Overall Anxiety Severity and Impairment Scale (OASIS) from baseline to 12 weeks. It consists of five items that measure the frequency and severity of anxiety, as well as level of avoidance, work/school/home interference, and social interference associated with anxiety. Respondents select among five different response options for each item, which are coded 0-4 and summed to obtain a total score. Score range is 0-20. The lower score is better in symptoms.

    Time frame: from baseline to 12 weeks

  14. Changes in measuring the depression symptoms

    Measure the depression in schizophrenia without overlap with negative symptoms and extrapyramidal symptoms by using the Calgary Depression Scale for schizophrenia (CDSS) from baseline to 12 weeks. it includes 9 items in the scale. All ratings of the items are defined according to operational criteria from 0-3. The CDSS depression score is obtained by adding each of the item scores. Score range is 0-27, which is the lower score is better.

    Time frame: from baseline to 12 weeks

  15. Changes in biomarkers that occur in relation to symptomatic improvement with adjunctive cannabidiol compared to placebo.

    Measure the neuroimaging (Magnetic resonance imaging (MRI)) from baseline to 12 weeks if participant consents to it. The Magnetic resonance imaging (MRI) scan includes: T1 - brain structure T2 FLAIR - brain structure / clinical reporting Neuromelanin sensitive MRI - neuromelanin content of substantial nigra (proxy of dopamine activity) Magnetic Resonance Spectroscopy of the anterior cingulate cortex - metabolites e.g. glutamate Resting state fMRI - bold activation during "rest" or free mind wandering

    Time frame: baseline and 12 weeks

  16. Changes in biomarkers that occur in relation to symptomatic improvement with adjunctive cannabidiol compared to placebo.

    Measure the microbiome samples from baseline to 12 weeks if participant consents to it. The gut-microbiome (the microorganisms e.g. bacteria, normally found in participant's gut) is likely to be at play in determining whether participant respond or experience side effects from CBD. Two tubes of stool samples to be collected at two time points(baseline and week 12) if participant consent to it.

    Time frame: baseline and 12 weekds

  17. Changes in biomarkers that occur in relation to symptomatic improvement with adjunctive cannabidiol compared to placebo.

    Measure the blood samples for central lab assessment including (Epi)genetics, proteomics, inflammation, metabolomics, Redox markers from baseline to 12 weeks if participant consents to it.

    Time frame: from baseline to 12 weeks

Other outcomes

  1. Change in overall patient impression of severity and improvement

    Change in overall patient impression, assessed through Patient Global Impression of Improvement and Severity (PGI-I/S) scales from baseline to 12 weeks. The Patient Global Impression of Improvement (PGI-I) is a single question asking the patient to rate how their psychotic symptoms is now compared to the previous study visit on a scale of 1. very much better to 7. very much worse. The lower score is better in symptoms' improvement. The Patient Global Impression of Severity (PGI-S) is a single question asking the patient to rate how their psychotic symptoms is now on a scale of 1. not present to 7. very severe. The lower score is better in symptoms.

    Time frame: from baseline to 12 weeks

07

Study locations

15 sites
08

References and documents

Individual participant data

Plan to share: Yes — Please contact the sponsor, who will provide instructions for submitting a data request. All data can be requested, regardless of the location of the requesting party.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data and supporting documents will become available once the primary papers are available in the scientific domain.

Access criteria: These will be provided by the sponsor to the requesting party.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Sep 2028, 20 months later.

Of 26 phase 3 interventional studies under Psychotic Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 72. This study's planned 20 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Jan 2027, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Jan 8, 2026
StartEst.
Jan 2027was Jun 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 2026→Jan 2027
Oct 8, 2026
Contact
Study contact's phone or email changed: none listed→•••6137. See the current contact
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Start date Jun 2026→Jan 2027
    Contact Study contact's phone or email changed: none listed→•••6137. See the current contact
    + 1 other change: site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07326124
Collaborators
Wellcome Trust, Cambridge Cognition Ltd, Cambridgeshire and Peterborough NHS Foundation Trust, Oxford Health NHS Foundation Trust, West London NHS Trust, Charite University, Berlin, Germany, University of Cologne, Ludwig-Maximilians - University of Munich, University Hospital Frankfurt, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, The Sheba Fund for Health Services and Research, Shalvata Mental Health Center, Geha Mental Health Center, Amsterdam University Medical Center, National and Kapodistrian University of Athens, Hospital General Universitario Gregorio Marañon, Hospitales Universitarios Virgen del Rocío, University of Campania Luigi Vanvitelli, Psychiatric University Hospital, Zurich, Douglas Hospital Research Centre
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Jan 2027 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Jared Robinson
Contact
steptrials@phc.ox.ac.uk
07900206137
Susan Zhao
Contact
steptrials@phc.ox.ac.uk

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion